

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-20 (canceled).

**B1**  
Claim 21 (New). An antibody to a protein having cortistatin-like activity wherein said protein is selected from the group consisting of SEQ ID NOs 23, 24 and 26, positions 44 to 74 of SEQ ID NO 26, positions 77 to 105 of SEQ ID NO 26, and sequences having at least about 95% amino acid residue similarity to SEQ ID NOs 23, 24 and 26.

Claim 22 (New). The antibody of claim 21, wherein the antibody is substantially free from immunoreaction with neuropeptides other than cortistatin.

Claim 23 (New). The antibody of claim 21, wherein the antibody is a monoclonal antibody.

Claim 24 (New). An immunologically active fragment of an antibody of claim 21 selected from the group consisting of the Fab, Fab', F(ab')<sub>2</sub> and F(v) fragments.

Claim 25 (New). A method of making an antibody of claim 21, comprising the steps of:

- (i) immunizing a mammal with an inoculum containing an immunologically effective amount of a cortistatin polypeptide to induce in the mammal antibody molecules having immunospecificity to the cortistatin polypeptide;
- (ii) collecting the antibody molecules; and
- (iii) isolating the antibody molecules that have immunospecificity to the cortistatin polypeptide.

Claim 26. (New) A method of making an antibody of claim 23, comprising the steps of:

- (i) initiating a monoclonal hybridoma culture with a nutrient medium containing a hybridoma that produces and secretes antibody molecules with cortistatin specificity;
- (ii) maintaining the culture under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium;
- (iii) collecting the antibody-containing medium; and
- (iv) isolating the antibody molecules that have cortistatin specificity.

Claim 27 (New). An hybridoma cell that produces a monoclonal antibody of claim 23.

Claim 28 (New). A pharmaceutical composition comprising an antibody of claim 21 and a pharmaceutically acceptable adjuvant.

Claim 29 (New). An antibody to a protein having cortistatin-like activity wherein said protein is selected from the group consisting of SEQ ID NOs 2, 6, 7, 8 and 9 and sequences having at least about 95% amino acid residue similarity to SEQ ID NOs 2, 6, 7, 8 or 9.

Claim 30 (New). The antibody of claim 29, wherein the antibody is substantially free from immunoreaction with neuropeptides other than cortistatin.

Claim 31 (New). The antibody of claim 29, wherein the antibody is a monoclonal antibody.

Claim 32 (New). An immunologically active fragment of an antibody of claim 29 selected from the group consisting of the Fab, Fab', F(ab')<sub>2</sub> and F(v) fragments.

Claim 33 (New). A method of making an antibody of claim 29, comprising the steps of:

(i) immunizing a mammal with an inoculum containing an immunologically effective amount of a cortistatin polypeptide to induce in the mammal antibody molecules having immunospecificity to the cortistatin polypeptide;

(ii) collecting the antibody molecules; and

(iii) isolating the antibody molecules that have immunospecificity to the cortistatin polypeptide.

Claim 34. (New) A method of making an antibody of claim 31, comprising the steps of:

(i) initiating a monoclonal hybridoma culture with a nutrient medium containing a hybridoma that produces and secretes antibody molecules with cortistatin specificity;

(ii) maintaining the culture under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium;

(iii) collecting the antibody-containing medium; and

(iv) isolating the antibody molecules that have cortistatin specificity.

Claim 35 (New). An hybridoma cell that produces a monoclonal antibody of claim 31.

Claim 36 (New). A pharmaceutical composition comprising an antibody of claim 29 and a pharmaceutically acceptable adjuvant.

Claim 37 (New). An antibody to a protein having cortistatin-like activity wherein said protein is selected from the group consisting of SEQ ID NOS 5, 10, 11 and 12 and sequences having at least about 95% amino acid residue similarity to SEQ ID NOS 5, 10, 11 or 12.

Claim 38 (New). The antibody of claim 37, wherein the antibody is substantially free from immunoreaction with neuropeptides other than cortistatin.

Claim 39 (New). The antibody of claim 37, wherein the antibody is a monoclonal antibody.

Claim 40 (New). An immunologically active fragment of an antibody of claim 37 selected from the group consisting of the Fab, Fab', F(ab')<sub>2</sub> and F(v) fragments.

Claim 41 (New). A method of making an antibody of claim 37, comprising the steps of:

- (i) immunizing a mammal with an inoculum containing an immunologically effective amount of a cortistatin polypeptide to induce in the mammal antibody molecules having immunospecificity to the cortistatin polypeptide;
- (ii) collecting the antibody molecules; and
- (iii) isolating the antibody molecules that have immunospecificity to the cortistatin polypeptide.

Claim 42. (New) A method of making an antibody of claim 39, comprising the steps of:

- (i) initiating a monoclonal hybridoma culture with a nutrient medium containing a hybridoma that produces and secretes antibody molecules with cortistatin specificity;
- (ii) maintaining the culture under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium;
- (iii) collecting the antibody-containing medium; and
- (iv) isolating the antibody molecules that have cortistatin specificity.

Claim 43 (New). An hybridoma cell that produces a monoclonal antibody of claim 39.

Claim 44 (New). A pharmaceutical composition comprising an antibody of claim 37 and a pharmaceutically acceptable adjuvant.